Akorn says the completed divestment of its branded ophthalmic portfolio to Théa Pharma will enable the firm to focus on growth areas including human generics and animal care.
Financial details were not revealed of the transaction, which follows Akorn going through Chapter 11 bankruptcy proceedings and a sale...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?